&nbsp;

Best Practice Guidance for Patient-Specific Quality Assurance (PSQA) for IMRT and VMAT Plan Delivery Verification

Nov 2019

Document

BiosimilarPatients.pdf

Nov 2019

Document

BiosimilarPatients-FR.pdf

Nov 2019

Regimen

BORTCYCDOXPRED+R

Cancer Type:

Hematologic

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

ODB - General Benefit

prednisone

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Bortezomib - Previously Untreated Transplant Ineligible Mantle Cell Lymphoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2023

Regimen

BEND+POLA+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade

Intent: Palliative

Funding:

New Drug Funding Program

Polatuzumab Vedotin with Bendamustine and Rituximab (Biosimilar) - Relapsed or Refractory Diffuse Large B-cell Lymphoma

New Drug Funding Program

Polatuzumab Vedotin with Bendamustine and Rituximab (Biosimilar) - Relapsed or Refractory Diffuse Large B-cell Lymphoma

New Drug Funding Program

Polatuzumab Vedotin with Bendamustine and Rituximab (Biosimilar) - Relapsed or Refractory Diffuse Large B-cell Lymphoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

BINIENCO+CETU

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Drugs Used:

binimetinib (Unfunded),

encorafenib (Unfunded),

cetuximab (Unfunded)

... Show more tags

Quick Link(s):

Regimen Monograph

Jul 2023

Regimen

BELA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Drugs Used:

belantamab mafodotin (Unfunded)

... Show more tags

Quick Link(s):

Regimen Monograph

Mar 2020

Document

BiopsyAddendeumTemplate

May 2020

Document

2019_Ontario_Medical_Physics_Residency_Program_CAMPEP_Statistics_Final

Jun 2020

Document